Mopiravir is an isopropyl prodrug of [N4 hydroxycytidine]. As the oral bioavailability of non-human primates increases, it is hydrolyzed in the body and distributed into tissues, becoming an active form of 5 '- triphosphate. The binding of active drugs to the genome of RNA viruses leads to the accumulation of mutations known as viral error disasters. Recent studies have shown that EIDD-2801 inhibits the replication of human and bat coronaviruses (including SARS-CoV-2) in mouse and human airway epithelial cells. Anti [remdesivir] mutant mouse hepatitis virus has also been shown to be more sensitive to N4-hydroxycytidine.